Volume 13, Number 6—June 2007
Multidrug-Resistant Acinetobacter baumannii
Highlight and copy the desired format.
|EID||Krcmery V, Kalavsky E. Multidrug-Resistant Acinetobacter baumannii. Emerg Infect Dis. 2007;13(6):943-944. https://dx.doi.org/10.3201/eid1306.070064|
|AMA||Krcmery V, Kalavsky E. Multidrug-Resistant Acinetobacter baumannii. Emerging Infectious Diseases. 2007;13(6):943-944. doi:10.3201/eid1306.070064.|
|APA||Krcmery, V., & Kalavsky, E. (2007). Multidrug-Resistant Acinetobacter baumannii. Emerging Infectious Diseases, 13(6), 943-944. https://dx.doi.org/10.3201/eid1306.070064.|
To the Editor: In the January 2007 issue of Emerging Infectious Diseases, Sunenshine et al. (1) described their finding of an independent association between patients with multidrug-resistant (MDR) Acinetobacter infection and increased hospital and intensive care unit (ICU) length of stay compared with that for patients with antimicrobial drug–susceptible Acinetobacter infection. The authors did not, however, find a statistically significant difference in mortality rates between the 2 groups of patients.
Acinetobacter infections frequently occur in severely ill ICU patients with other chronic illnesses or prolonged hospitalizations. We analyzed data for 27 neutropenic cancer patients with A. baumannii–associated bacteremia (15 with MDR and 12 with drug-susceptible A. baumannii infections) but no other chronic illness. We considered A. baumannii strains to be MDR if they were resistant to amikacin, meropenem, and ciprofloxacin. Univariate analysis (Epi Info 2000; Centers for Disease Control and Prevention, Atlanta, GA, USA) showed that most of the bacteremic episodes were associated with certain risk factors, such as catheter insertion, neutropenia, acute leukemia, and previous prophylactic treatment with quinolones or therapeutic treatment with cephalosporins or carbapenems (meropenem or imipenem) (Table).
Septic shock developed in 4 (14.8%) of the 27 neutropenic patients with A. baumannii–associated bacteremia, and 2 (7.4%) of the 27 died (Table). However, we did not find a statistically significant association between death among patients with bacteremia caused by MDR A. baumanni (1 death) compared with death among those with bacteremia caused by A. baumannii strains susceptible to the carbapenems, ciprofloxacin, and amikacin (1 death) (Table). This finding is similar to that described by Sunenshine et al. (1) in the general ICU population and in neutropenic cancer patients with bacteremia; however, multivariate analysis was not conducted to control for severity of illness and coexisting illness. In conclusion, neutropenic cancer patients with bacteremia due to MDR A. baumannii infection do not appear to be at increased risk for death compared with patients with bacteremia due to antimicrobial drug–susceptible A. baumannii.
This work was supported by grant 06/07/VEGA of the Ministry of Education of Slovak Republic and approved by the Ethics Committee of St Elizabeth Cancer Institute in Bratislava.
- Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97–103.
- Table. Risk factors and outcome for 27 neutropenic cancer patients with bacteremia due to multidrug-resistant (MDR) or drug-susceptible Acinetobacter baumannii infection
Please use the form below to submit correspondence to the authors or contact them at the following address:
Vladimir Krcmery, St Elizabeth School of Health and Social Sciences, Department of Oncology, Heydukova 10, 812 50 Bratislava, Slovakia;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 05, 2010
- Page last updated: July 05, 2010
- Page last reviewed: July 05, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)